Srinivas Akkaraju Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 3 months, 1 week ago
Srinivas Akkaraju has an estimated net worth of at least $15.8 million*, as of Oct. 29, 2025. They own 6.4 million shares of SRRK stock. They have sold 1.2 million shares of SRRK stock since 2021, for an estimated $578,320.
Srinivas Akkaraju $SRRK SEC Form 4 Insider Trading
Srinivas Akkaraju has filed a total of 13 insider trades in $SRRK since 2021. Their most recent trade was a purchase of 4,403 shares, made on Oct 07, 2025. Their largest trade was a purchase of 2.2 million shares, made on Oct 16, 2023. We estimate that they now own 6.4 million shares of $SRRK, worth an estimated $15.2 million.
Insider Trading at $SRRK
There have been a total of 139 insider trades reported at $SRRK since 2021, with 8.6 million shares purchased and 4.6 million shares sold. The most active insider traders in $SRRK stock have been Mo Qatanani, Edward H Myles, and Jing L. Marantz. The most recent trade was a sale of 2,119 shares reported by Mo Qatanani (CHIEF SCIENTIFIC OFFICER), made on Jan 22, 2026.
History of Insider Stock Trades by Srinivas Akkaraju
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
ALMS
|
Purchase | 588,235 | Jan 09, 2026 | Jan. 13, 2026, 7:20 p.m. |
SRRK
|
Purchase | 4,403 | Oct 07, 2025 | Dec. 16, 2025, 10:07 p.m. |
SRRK
|
Purchase | 12,400 | Oct 07, 2025 | Dec. 16, 2025, 10:07 p.m. |
SRRK
|
Purchase | 12,796 | Oct 07, 2025 | Dec. 16, 2025, 10:07 p.m. |
ALMS
|
Purchase | 64,969 | Dec 05, 2025 | Dec. 9, 2025, 8:13 p.m. |
ALMS
|
Purchase | 70,028 | Dec 05, 2025 | Dec. 9, 2025, 8:13 p.m. |
ALMS
|
Purchase | 51,380 | Dec 05, 2025 | Dec. 9, 2025, 8:13 p.m. |
ALMS
|
Purchase | 66,027 | Dec 04, 2025 | Dec. 4, 2025, 9:11 p.m. |
ALMS
|
Purchase | 96,000 | Dec 02, 2025 | Dec. 4, 2025, 9:11 p.m. |
ALMS
|
Purchase | 100,000 | Dec 03, 2025 | Dec. 4, 2025, 9:11 p.m. |
ALMS
|
Purchase | 48,537 | Nov 26, 2025 | Dec. 3, 2025, 10:06 p.m. |
ALMS
|
Purchase | 38,702 | Nov 28, 2025 | Dec. 3, 2025, 10:06 p.m. |
ALMS
|
Purchase | 86,350 | Dec 01, 2025 | Dec. 3, 2025, 10:06 p.m. |
ALMS
|
Purchase | 125,743 | Nov 20, 2025 | Nov. 24, 2025, 7:50 p.m. |
ALMS
|
Purchase | 137,772 | Nov 19, 2025 | Nov. 19, 2025, 9:46 p.m. |
ALMS
|
Purchase | 914 | Nov 17, 2025 | Nov. 19, 2025, 9:46 p.m. |
ALMS
|
Purchase | 102,652 | Nov 18, 2025 | Nov. 19, 2025, 9:46 p.m. |
ALMS
|
Purchase | 276,179 | Nov 13, 2025 | Nov. 17, 2025, 5:59 p.m. |
SRRK
|
Purchase | 56,703 | Oct 03, 2025 | Oct. 7, 2025, 8:59 p.m. |
SRRK
|
Purchase | 18,414 | Oct 06, 2025 | Oct. 7, 2025, 8:59 p.m. |
SRRK
|
Purchase | 80,863 | Oct 06, 2025 | Oct. 7, 2025, 8:59 p.m. |
SRRK
|
Purchase | 13,748 | Oct 06, 2025 | Oct. 7, 2025, 8:59 p.m. |
SRRK
|
Purchase | 319,700 | Oct 03, 2025 | Oct. 7, 2025, 8:59 p.m. |
SRRK
|
Purchase | 11,011 | Oct 03, 2025 | Oct. 7, 2025, 8:59 p.m. |
MLYS
|
Purchase | 588,235 | Sep 04, 2025 | Sept. 8, 2025, 8:07 p.m. |
ALMS
|
Purchase | 159,920 | May 02, 2025 | May 6, 2025, 6:52 p.m. |
ALMS
|
Purchase | 138,368 | May 05, 2025 | May 6, 2025, 6:52 p.m. |
ALMS
|
Purchase | 22,002 | May 05, 2025 | May 6, 2025, 6:52 p.m. |
MLYS
|
Purchase | 600,000 | Mar 13, 2025 | March 17, 2025, 9:04 p.m. |
SRRK
|
Sale | 510,000 | Oct 07, 2024 | Oct. 7, 2024, 8:55 p.m. |
SRRK
|
Sale | 510,000 | Oct 07, 2024 | Oct. 7, 2024, 8:55 p.m. |
SRRK
|
Sale | 155,713 | Oct 07, 2024 | Oct. 7, 2024, 8:55 p.m. |
SYRS
|
Purchase | 904,977 | Dec 21, 2023 | Dec. 26, 2023, 6:24 p.m. |
SRRK
|
Purchase | 2.2 million | Oct 16, 2023 | Oct. 18, 2023, 5:46 p.m. |
MLYS
|
Purchase | 937,500 | Feb 14, 2023 | Feb. 16, 2023, 5:54 p.m. |
KDNY
|
Purchase | 570,000 | May 27, 2022 | June 1, 2022, 4:13 p.m. |
KDNY
|
Purchase | 1.2 million | Nov 15, 2021 | Nov. 17, 2021, 1:05 p.m. |
KDNY
|
Purchase | 208,500 | Aug 18, 2021 | Aug. 19, 2021, 8 p.m. |
GRPH
|
Purchase | 15,000 | Jun 29, 2021 | June 30, 2021, 8 p.m. |
GRPH
|
Purchase | 485,000 | Jun 29, 2021 | June 30, 2021, 8 p.m. |
$SRRK Executives and Stock Owners with Insider Trades
-
Mo Qatanani, CHIEF SCIENTIFIC OFFICER
-
Edward H Myles, COO & CFO
-
Jing L. Marantz, CHIEF MEDICAL OFFICER
-
Caryn Parlavecchio, CHRO
-
Junlin Ho, GENERAL COUNSEL
-
Tracey Sacco, Chief Commercial Officer
-
Akshay Vaishnaw, President of R&D
-
Edward H Myles, Chief Financial Officer
-
Jay T. Backstrom, CHIEF EXECUTIVE OFFICER
-
Mo Qatanani, SVP AND HEAD OF RESEARCH
-
Tracey Sacco, CHIEF COMMERCIAL OFFICER
-
David Hallal, Chief Executive Officer
-
Erin Moore, Interim PFO and PAO
-
Keith Woods, Chief Operating Officer
-
Vikas Sinha, Chief Financial Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.